Latest From Nevro Corp.
Abbott won US FDA approval for its Proclaim XR spinal cord stimulator. The device offers lower-dose and recharge-free neurostimulation for patients with chronic pain with a battery life for up to 10 years.
Chronic pain treatment company Nevro has filed suit against rival Stimwave Tech alleging patent infringement.
Starts & Stops: Boston Scientific Launches New Lotus TAVR Trial, Medtronic Starts Study Of SynchroMed II Pain Pump
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Jan. 7 through Jan. 27, including announcements from Medtronic, QT Vascular, Boston Scientific, and Shockwave.
Nevro and Boston Scientific have resolved a patent dispute involving spinal cord stimulation technologies.
- Implantable Devices
- Therapeutic Areas
- Neurology, Nervous System
- NBI Development Inc.
- North America
- Parent & Subsidiaries
- Nevro Corp.
- Senior Management
D. Keith Grossman, PhD, Pres. & CEO
Andrew Galligan, CFO
David Caraway, MD, PhD, CMO
Patrick Schmitz, VP, Operations
Niamh Pellegrini, Chief Commercial Officer
- Contact Info
Phone: (650) 251-0005
1800 Bridge Parkway
Redwood City, CA 94065
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.